

PRESS RELEASE

Lund 5 December 2017

Spago Nanomedical select ChemConnection for SpagoPix production to supply clinical trials

Spago Nanomedical AB has signed an agreement with ChemConnection BV, a well-established contract manufacturer with extensive experience in the GMP-production of nanomedical products, for the manufacture of the SpagoPix product candidate SN132D for clinical trials.

The SpagoPix project is advancing towards clinical trials and the product candidate SN132D is currently undergoing regulatory preclinical tests to generate the toxicity and safety data required to initiate human studies.

The production of material will commence in the first half of 2018. Tech transfer in which Spago Nanomedical transfers the production process developed by the company during the past year, starts immediately.

"We look forward to starting the GMP production of SN132D and continue preparations for clinical trials," says Oskar Axelsson, CSO of Spago Nanomedical.

"We are proud that we can contribute to the development of this exciting new product with the manufacture of clinical batches" says Gerjan Kemperman, CEO of ChemConnection.

For further information, contact Mats Hansen, CEO Spago Nanomedical AB, +46 767 764294, mats.hansen@spagonanomedical.se.

Spago Nanomedical (AktieTorget Stockholm: SPAG) develops nanomaterials for diagnosis and treatment of cancer. The company's development focuses primarily on the cancer-selective MRI contrast agent SpagoPix and the project Tumorad, for Radionuclide Therapy against Cancer. The company's business model is based on developing projects from explorative to regulatory preclinical or early clinical phase, then outsourcing or entering into partnerships for further development of projects to market. Spago Nanomedical aims to continuously expand patent protection for the projects and cooperate for this purpose with established and reputable patent agencies. For more information, see www.spagonanomedical.se.

SpagoPix is a contrast agent based on nanoparticles and manganese that can provide improved cancer diagnosis with magnetic resonance imaging (MRI). By offering high precision and very good enhancement of tumors and metastases in MRI images, the possibilities for correct diagnosis of

cancer increase. Improved diagnosis with MRI provides an increased chance of effective treatment for the patient.

The information in this press release, is information that Spago Nanomedical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU) No 596/2014. The information was provided by the above contact person for publication on 5 December 2017.